Vaccines have always been one of the most potent weapons in humanity’s long battle against disease. With the rapid development of science and technology, a new type of vaccine, the subunit vaccine, is gradually emerging, bringing new hope for preventing and controlling human and animal diseases.
Conventional vaccines contain the complete or partial structure of the pathogen. Although they are effective in stimulating an immune response, they may also bring about some adverse reactions due to the presence of other components of the pathogen. Subunit vaccines, conversely, are unique in that they select only key parts of the pathogen that are immunogenic, such as specific proteins or polysaccharides, as antigenic components. This precise design makes subunit vaccines extremely safe. By removing the parts of the pathogen that can cause adverse reactions, the vaccinated animal receives immune protection while the risk of side effects is significantly reduced.
Subunit vaccines are no less effective than traditional vaccines in terms of immunization effectiveness. The carefully selected antigenic components precisely stimulate the body’s immune system to produce a highly targeted immune response. Numerous clinical trials have shown that subunit vaccines can induce the body to produce high levels of specific antibodies, forming a strong defense barrier against the target pathogen. Moreover, the immune response is long-lasting, providing effective protection for a long period and reducing the need for frequent vaccinations.
Leading international animal health companies have launched a series of animal subunit vaccines. For example, the boehringer-ingelheim PCV 2 type subunit vaccine, MSD APP subunit vaccine, CEVA Vectormune FP-LT subunit vaccine, etc., have all received global recognition and feedback. In China, dozens of varieties of animal subunit vaccines have been approved for marketing. Subunit vaccines are sold and used for poultry, pigs, cattle, sheep, and pets. Subunit vaccines have already demonstrated high recognition from customers and strong market potential.
WIXBIO has formed a strong strategic partnership with over 20 animal vaccine enterprises and R&D organizations in China. WIXBIO has the only priority in the promotion and sales of various new animal vaccine products; WIXBIO has been authorized and supported by the national scientific research platform in the production and R&D technology of new vaccines, and it can provide global animal protection partners with the transfer of technology patents and training of talents, as well as diagnose the clinical difficulties at the breeding end with video diagnostics and put forward solutions.
The cooperation models for new subunit vaccines:
- Exclusive agency: WIXBIO signs an exclusive agency agreement with the distributor in the fixed distribution area. The distributor with the agency right is responsible for completing the registration of the Newcastle disease Gene-VII marked inactivated vaccine in its agent country and forming sales after obtaining the registration certificate.
- Technical cooperation: This plan applies to animal vaccine manufacturers. After signing the agreement, the property owner of Newcastle Disease Gene-VII labeled inactivated vaccine production technology will provide training and guidance to the partners on all relevant technologies, such as research and development, production, and quality inspection of the vaccine until the partners produce qualified products.
- Export of subunit vaccine semi-finished products: The semi-finished vaccine products produced in China are exported to the customer’s country. The local production enterprises will conduct subsequent processing and filling and sell the products locally. This method can quickly establish cooperation and avoid the considerable time and capital costs caused by the long registration period.
The S protein has a trimeric structure, and the expressed antigen must be identical. Otherwise, the immunogenicity will be poor.
The advantages and characteristics of the subunit production technology transfer and semi-finished products owned by WIX Biotech: The company’s core technology is protein genomics technology.
- Novo Antigen Discovery
- Novo Protein Refinement
- Novo Viral Vector Discovery
PCV2 Electron microscopic image of subunit vaccine
WIXBIO-VLP VLP assembled by other brands
Conclusion: The WIXBIO subunit vaccine has a high assembly rate, clear structure, stable chemical bonds, and strong immunogenicity.
Partially exportable semi-finished products of subunits：
- Swine: CSF E2+PRV+PCV2 (Classical Swine Fever+Pseudo Rabies Virus+Porcine Circovirus Virus)
- Swine: PEDV+TG+RV (Porcine Epidemic Diarrhea Virus+Transmissible Gastroenteritis+Rota Virus )
- Bovine：BVD+IBR+RV+HSC(A+B)+Clostridium (9 types )
